ASM Program 2021

 

Tuesday 12 October 2021 AEDT
From 10.00 | AEDT

Registration open: Collect name tags & satchel bags

MEETING ROOM
Promenade 1st Floor
Tues: 11.00 - 12.30 | AEDT

Combined Study Coordinator and Consumer Forum
Co-Chairs: Jan Mumford and Roslynn Murphy


11.00 – 11.05 Welcome and introduction

11.05 – 11.20 Health literacy of cancer patients
Presenter: Rachel Cameron

11.20 – 11.40  Adaptive Trial Design
Presenter: Kylie Shackleton

11.40 – 12.00 Learnings & Adaptations from COVID-19 – perspectives from Carer
Presenter: Gillian Worden

Learnings & Adaptations from COVID-19 – perspectives from Study Coordinator
Presenter: Searalen Chinnathumby

12.00 – 12.20 New Zealand – GI oncology trials (landscape/overview/treatment) 
Presenter: Sarah Benge

12.20 – 12.30 Q & A

MEETING ROOM
Fitzroy Ballroom
Welcome Lunch | 12.30 - 13.30 Promenade 1st Floor
Tues: 13.30 - 15.00 | AEDT

Study Coordinator Meeting 1
Co-Chairs: Laura Carolan and Sally Dean


13.30 – 13.40 Welcome and introduction

13.40 – 14.10 Statistics and Data Management
Presenter: Siavash Foroughi

14.10 – 14.30 Conducting Clinical Trials in New Zealand
Presenter: Sarah Benge

14.30 – 15.00 Implementing Teletrials
Presenter: Narelle McPhee

MEETING ROOM
Fitzroy Ballroom
Tues: 13.30 - 15.00 | AEDT

Mini-Preceptorship 1 – sponsored by Servier

Colorectal Cancer (early)

Co-Convenors:
Jeanne Tie (Medical Oncologist)
Derrick Siu (Medical Oncologist)
Sarah Maloney (Medical Oncologist)

Preceptors:
Rob Ramsay (Translational Researcher)
Deme Karikios (Medical Oncologist)
Sam Ngan (Radiation Oncologist)
Frank Frizelle (Surgeon)

MEETING ROOM
Victoria Suites 2
Afternoon Tea | 15.00 - 15.30 Promenade 1st Floor
Tues 15.30 - 16.30 Promenade 1st Floor | AEDT

Study Coordinator Meeting 2
Co-Chair: Roslynn Murphy and Evonne Tim


15.30 – 16.00 Project management in clinical trials: COVID-19
Presenter: Kylie Shackleton

16.00 – 16.30 Early versus Phase Trials
Presenter: James Lynam

MEETING ROOM
Victoria Suites 2
Tues 15.30 - 17.00 | AEDT

Mini-Preceptorship 2 – sponsored by Servier

Colorectal Cancer (metastatic/peritoneal)

Co-Convenors:
Deme Karikios (Medical Oncologist)
Derrick Siu (Medical Oncologist)
Sarah Maloney (Medical Oncologist)

Preceptors:
Rob Ramsay (Translational Researcher)
Jeanne Tie (Medical Oncologist)
Plus TBC (Surgeon)

MEETING ROOM
Victoria Suites 2
Tues 17.30 - 19.00 | AEDT

ENGAGE Community Forum

MC:  Shalin Naik (WEHI; Ask the Doctor, ABC TV)

Panelists:
John Zalcberg OAM (co-founder of the AGITG)
Dorothy Keefe (CEO of Cancer Australia)
Jeanne Tie (Medical Oncologist)
Rob Ramsay (Translational Researcher)
Lara Lipton (Medical Oncologist)
Jeff Cuff (AGITG Consumer Advisory Panel Member)
Belinda Steer (Dietician)
Michael Jefford (Medical Oncologist)

MEETING ROOM
La Trobe Ballroom
Wednesday 13 October 2021 AEDT
From 06.45 | AEDT

Registration open

MEETING ROOM
Promenade 1st Floor
Wed: 07.45 - 08.45 | AEDT

Keynote Breakfast Session
Co-Chairs: John Zalcberg and Stephanie Lim


Evolution and revolution of clinical trials in GI cancer: endpoints and magnitude of clinical benefits

The gold standard for establishing the efficacy of new cancer therapies is a phase III randomized controlled trial. Over the past 3 decades, there has been a marked shift in the primary endpoint of cancer clinical trials with increasing use of surrogate endpoints, as well as an increase in trial sample size. Several reports have shown that the incremental gain of new cancer therapies is getting smaller over time. The expanding number of systemic therapy options has raised important considerations regarding patient-reported toxicity and financial toxicity. It is therefore imperative that regulatory bodies carefully consider which treatments will offer the largest clinical benefit within a sustainable health care system. To this end, both ESMO and ASCO has established task forces to rank the magnitude of benefit of the new anti-cancer agents.

Presenter: Alberto Sobrero

MEETING ROOM
Latrobe Ballroom
Wed: 09.00-10.30 | AEDT

Opening Plenary
Chair: Lorraine Chantrill


Back to the Future: using the retrospectoscope

How did we get to where we are now? Reflecting on 30 years of AGITG.

Panel discussion with AGITG Pioneers

MEETING ROOM
Arthur Streeton Auditorium
Morning Tea | 10.30 - 11.00 Grand Ballroom
Wed: 11.00 - 13.00 | AEDT

AGITG Early Colorectal Cancer Trials
Co-Chairs: Niall Tebbutt and Shehara Mendis


Presentations by trial investigators for:

  • SPAR
  • DYNAMIC-III & DYNAMIC-Rectal
  • ASCOLT
  • RENO
  • OXTOX
  • FORECAST-1
  • LICPIC

Followed by:

AGITG Early Colorectal Cancer Trials Portfolio – How does this fit in to the International Context?

Presenter: Tim Price

Followed by Q&A

MEETING ROOM
Arthur Streeton Auditorium
Lunch | 13.00 - 14.00 Grand Ballroom
Wed: 14.00 - 16.00 | AEDT

AGITG Advanced Colorectal Cancer Trials
Co-Chairs: Chris Karapetis and Margaret Lee


Presentations by trial investigators for:

  • ALT-TRACC
  • MONARCC
  • RoLaCaRT-1
  • LIBERATE
  • MODULATE
  • VADER
  • RESOLUTE
  • GENESCREEN-5FU

Followed by:

AGITG Advanced Colorectal Cancer Trials Portfolio – How does this fit in to the International Context?

Presenter: Sue Anne McLachlan

Followed by Q&A

MEETING ROOM
Arthur Streeton Auditorium
Wed: 14.00 - 16.00 | AEDT

Radiation Oncology Workshop Oesophageal Cancer
Co-Chairs: Meredith Johnston and Dominique Lee


Gullets and Mullets: What’s changed in 30 years of oesophageal cancer treatment (and hairstyles)?

It has been almost thirty years since the RTOG 85-01 trial established definitive CRT as the standard management for non-operative localised oesophageal cancer. During this time, patient demographics and tumour subtype distribution have changed, additionally radiation techniques an organ support during chemotherapy have improved dramatically. Despite a lack of randomised data directing radiation oncologists, greater interest in elective nodal irradiation, dose escalation, organ preservation, altered concurrent chemotherapy regimes and immunotherapy have laid the foundations for oesophageal and GOJ cancers to be increasingly complex. In this interactive radiation workshop, we discuss these controversies through case presentations.

International Presenter: Corrie Marijnen

International Presenter: Karin Haustermans

National Presenter: Trevor Leong

Case Studies

Panel discussion: Corrie Marijnen, Karin Haustermans and Trevor Leong

MEETING ROOM
La Trobe Ballroom
Afternoon Tea | 16.00 - 16.30 Grand Ballroom
Wed: 16.30 - 18.00 | AEDT

Multidisciplinary Workshop Rectal Cancer

Shifting Paradigm in the Multidisciplinary Management of Rectal Cancer
Co-Chairs: Hui-Li Wong and Julie Chu


The management of rectal cancer has evolved significantly over the past 2 decades. Emerging data are supporting a more personalised multidisciplinary treatment algorithm for a disease type which was once managed with a “one size fit all” approach. Recent treatment concepts include the incorporation of total neoadjuvant therapy (TNT), incorporation of watch-and-wait protocols for those patients who have achieved a clinical complete response following neoadjuvant therapy for organ preservation, selective approach for dissection of lateral pelvic lymph nodes, offering local excision to carefully selected patients, and tailoring neoadjuvant therapies to tumour biology, such as in patients with MSI-high tumour.

TNT: Is the evidence sufficient to change practise?
Presenter: Bridgette Ma

Current status of organ preservation in rectal cancer

APR – “abdominoperineal resection” or “A Procedure Redundant”. Organ preservation is now considered the standard in a range of cancers. As chemoradiotherapy, risk stratification and radiological surveillance techniques improve, organ preservation in appropriately selected rectal cancer patients is increasingly discussed in MDTs. This short presentation will describe the current state of play.
Presenter: Corrie Marijnen

Surgical presenter: TBC

Followed by two case presentations: A radiation oncologist and a medical oncologist present from different angles to stimulate the panel discussion:

Case study one:
Presenter: Radiation Oncologist

Case study two:
Presenter: Chia Yuen Chong

Panel Discussion: Bridgette Ma, Corrie Marijnen and Eva Segelov

MEETING ROOM
Arthur Streeton Auditorium
Welcome Reception and Poster Review | 18.00 - 20.00 Grand Ballroom
Thursday 14 October 2021 AEDT
From 06.45 | AEDT

Registration open

MEETING ROOM
Promenade 1st Floor
Thurs: 07.45 - 08.45 | AEDT

Keynote Breakfast Session: Practical Genomics in GI Cancer
Sponsored by Servier
Co-Chairs: Stephen Ackland and Oliver Sieber


Geoff Cooper first imaged Ras mutations as a driver of cancer at the cusp of the 1980s. “A Genetic model of colorectal carcinogenesis” by Fearon and Vogelstein published in 1988 had a huge impact as measured by ~14,000 citations; expanding our attention to three genes. DPD deficiency causing 5FU toxicity was first reported in 1985. These landmark reports are 4 decades ago and perhaps now is a good moment to reflect on how to exploit the massive amount of subsequent genomics knowledge into practice.

Screening for DPD deficiency: Should it be done before starting fluoropyrimidine?

Presenter:  Julien Taieb

Genomic sequencing in GI Cancer: What you need to know in the clinic

Presenter: Kortnye Smith

Followed by Q&A

MEETING ROOM
Latrobe Ballroom
Thurs: 09.00 - 10.45 | AEDT

New Concepts Symposium
Co-Chairs: Lorraine Chantrill and Katrin Sjoquist


The New Concepts Symposium is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to present embryonic new concepts for feedback and discussion with the audience as well as comments from international guests in terms of perspective, international interest and relevance. A good idea can be tested and a perception gained on whether to take the concept forward to a more formal review by the Upper or Lower GI Working Party. The identification of other AGITG members who may wish to assist in progressing the concept as an AGITG supported protocol is also possible. The winner of the Best New Concept Award will receive a $3,500 prize and a framed certificate. The runner up will receive a $1,500 prize and framed certificate. The Awards are presented at the Annual Scientific Meeting Dinner and details of the Award recipients are published on the AGITG website and in the Annual Report.

MEETING ROOM
Arthur Street Auditorium
Morning Tea | 10.45 - 11.15 Grand Ballroom
Thurs: 11.15 - 12.15 | AEDT

Best of the Best and Fast Forward – sponsored by Servier
Co-Chairs: Stephen Ackland and Oliver Piercey


The AGITG Annual Scientific Meeting accepts abstracts for posters for selection by the Executive Organising Committee.  Posters are displayed in the exhibition area. Four posters are chosen for presentation in the Best of the Best Session. Each presenter has seven minutes to present with three minutes for questions. Four posters are also chosen for Fast Forward presentation. Each presenter has three minutes to present with two minutes for questions.

The AGITG recognises excellence in the Posters and Fast Forward Sessions at each annual meeting. The winning presenter in the Posters Session receives a $3,500 prize and framed certificate. The winning presenter in the Fast Forward session receives $1,500 and a framed certificate. The Awards are presented at the Annual Scientific Meeting Dinner and details of the Award recipients are published on the AGITG website and in the Annual Report.

MEETING ROOM
Arthur Streeton Auditorium
Lunch | 12.15 - 13.15 Grand Ballroom
Thurs: 13.15 - 15.15 | AEDT

Translational Science Symposium
Co-Chairs: Vicki Whitehall and John Mariadason


The Ins and Outs of GI tumours

Seven experts each present for 15 minutes on a topic of their choice, followed by a 15 minute panel discussion

Technological underpinning of the FORECAST-1 Trial study
Presenter: Oliver Sieber

Early onset colorectal cancer
Presenter: Dan Buchanan

New Treatments for Bowel Cancer-ideas from the lab
Presenter: Susan Woods

Metabolic Reprogramming in Pancreatic Tumours
Presenter: Phoebe Phillips

Immunosuppression and therapy response in hepatocellular carcinoma
Presenter: Ankur Sharma

STAT pathway activation in CR
Presenter: Jennifer Huynh

Dual targeting HDACs and the EGFR/MAPK pathway in mCRC from idea to trial
Presenter: Laura Jenkins

Followed by a panel discussion

MEETING ROOM
Arthur Streeton Auditorium
Afternoon Tea | 15.15 - 15.45 Grand Ballroom
Thurs: 15.45 - 17.45 | AEDT

Translational Science Symposium 
Co-Chairs: Robert Ramsay and Laura Jenkins


Determinants of patient outcome, therapy response and new targets

It is proving unhelpful to consider colorectal tumours as a single entity. This is clearly demonstrated by genomic analyses into definable consensus molecular signatures that underpin marked differences in responses to standard of care therapies. Beyond these signatures the deep delving into the genetic drivers of CRC has been de rigueur and some are now showing exquisite and surprising responses to targeted agents. All that said it is truly remarkable how the immune milieu so impressively governs patient outcomes. Putting all this together, it is highly likely that advances for our patients will depend heavily on embracing these exciting developments as best practise.

Where to next with stratifying CRC by consensus molecular signatures?
Presenter: Jonathan Loree

At last there are agents to target the RAS/RAF pathway with precision
Presenter: Jayesh Desai

The tumour immune microenvironment over-arching our understanding of CRC – the development and implementation of the “Immunoscore” platform
Presenter: Jerome Galon

MEETING ROOM
Arthur Streeton Auditorium
AGITG 23rd Annual Meeting Reception | 19.00 - 20.00 Grand Ballroom
AGITG 23rd Annual Meeting Dinner | 20.00 - 23.00 Latrobe Ballroom
Friday 15 October 2021 AEDT
From 07.30 | AEDT

Registration open

MEETING ROOM
Promenade 1st Floor
Fri: 08.30 - 10.00 | AEDT

Keynote Breakfast Session: HCC

Current and Emerging Multimodality Treatment Options for Hepatocellular Carcinoma
Co-Chairs: Chris Nahm, Sumitra Ananda and Dominique Lee


The management of patients with hepatocellular carcinoma (HCC) is complex where treatment options are determined both by disease extent and the severity of underlying liver disease. Additionally, no single staging system is applicable to all patients and a wide variety of treatments are offered by different specialties: surgery, radiation oncology, medical oncology, hepatology and interventional radiology. New treatments and indications are also evolving rapidly, challenging attempts to generate algorithmic approaches to the treatment of HCC. It is therefore critical that individual patients undergo multidisciplinary evaluation and planning to generate an optimal management plan.

Presenters:
Ghassan Abou-Alfa
Simone Strasser
Dominique Lee
Pierce Chow

Panel discussion:
Chris Nahm, Sumitra Ananda, Dominique Lee, Ghassan Abou-Alfa, Simone Strasser and Pierce Chow

MEETING ROOM
Latrobe Ballroom
Fri: 10.15 - 11.15 | AEDT

AGITG Upper GI Cancer Research
Co-Chairs: Andrew Barbour & Bryan Chan


Presentations by trial investigators for:

  • NEO-IMPACT
  • ASCEND
  • DYNAMIC-Pancreas
  • MASTERPLAN & 3 sub studies

Followed by Q&A

MEETING ROOM
Arthur Streeton Auditorium
Morning Tea | 11.15 - 11.45 Grand Ballroom
Fri: 11.45 - 13.30 | AEDT

AGITG Upper GI Cancer Research (continued)
Co-Chairs: Lara Lipton & Mandi Maundura


Presentations by trial investigators for:

  • TOPGEAR
  • PALEO
  • NEO-CREATE
  • INTEGRATE IIa/b
  • CONTROL NETS & TR sub study
  • NABNEC
  • ALT-GIST
  • SSGXXII
  • ACTICCA-1

Followed by:

AGITG Upper GI Cancer Research Portfolio – How does this fit in to the International Context?
Presenter: David Ransom

Followed by Q&A

MEETING ROOM
Arthur Streeton Auditorium
Lunch | 13.30 - 14.30 Grand Ballroom
Fri: 14.30 - 15.30 | AEDT

Closing Plenary
Co-Chairs: Stephen Ackland & Lorraine Chantrill

AGITG into the Future: Strategy, Culture and Trial Design

For 30 years, the AGITG has been the premier cooperative GI trials group in the region, but the COVID-19 pandemic has shown that no one is immune from the need to adapt. Many current and future issues could affect the group’s survival and sustainability. Led by a panel of next-generation leaders, this session invites all members to ponder and discuss the future of the AGITG: What trial designs will we undertake in the next 5-10 years? How can we position ourselves to deliver them in the best possible way? How do we engage new talent to join the Group?

Presentation: John Zalcberg OAM

Presentation: David Lau

Followed by a Panel Discussion

MEETING ROOM
Arthur Streeton Auditorium
Close of ASM | 15.30
Buses depart to the Airport | 16.00